Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback